The abstract is read at the publisher; the summary is JClub's.
A single high-dose AAV gene therapy in Polg knockout neonate mice preserves respiratory chain activity in Purkinje cells and skeletal muscle and extends lifespan.
- Why it matters: POLG disease is incurable and early-onset forms are often fatal, but gene replacement has been limited by POLG cDNA size and lack of suitable mouse models.
- What they did: The study created a Polg KO mouse by inactivating Polg in parvalbumin-expressing neurons and fast-twitch skeletal muscle, then tested nine AAV vectors delivering human POL{gamma}A.
- The result: Two lead AAV candidates, given once to Polg KO neonates, delayed motor coordination deficits and prolonged survival, supporting preclinical feasibility for POLG disease gene replacement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.